新辅助化疗对肺癌患者肿瘤标记物及免疫指标的影响

目的观察术前行新辅助化疗对A期非小细胞肺癌患者的影响。方法142例A期非小细胞肺癌患者随机分为两组。实验组:先给予两个疗程的新辅助化疗,3周后行手术治疗,化疗方案为MVP或NVB DDP方案;对照组:确诊后直接行手术治疗。结果实验组术后心律失常发生率高于对照组,其余术后并发症发生率无显著差异(P>0.05);术后实验组NK细胞水平低于对照组(P<0.05),其余各项免疫指标无显著性差异(P>0.05)。实验组术后血清肿瘤标记物水平低于对照组(P<0.05)。结论新辅助化疗作为治疗A期非小细胞肺癌的一种方法是安全的,对患者免疫功能和术后并发症发生率的影响较小,并能明显降低患者术后血清肿瘤标记物水平。

The effects of neuadjuvant chemotherapy on tumor marker values and immunity index of lung cancer patients

Objective To observe the effects of neoadjuvant chemotherapy on immunity index, tumor marker values and operative complications of patients with IIIA stage non-small cell lung cancer (NSCLC).WT6HXMethods 142 cases of patients with IIIA stage NSCLC were randomly divided into two groups. The patients of the experimental group received chemotherapy in 2 courses, followd by surgery. The regimens included MVP or NVB DDP. The patients of the control group were treated only by operation.Results The accidence rate of arrhythmia in the experimental group was higher than that in the control group. No significant difference of other operative complications was found between the two groups (P>0.05). NK cells was lower in the experimental group than in the control group (P<0.05). There were no significant difference of other immunity index was found between the two groups (P>0.05). The tumor marker values in the experimental group was lower than that in the control group (P<0.05).Conclusion For the IIIA stage NSCLC patients, the preoperative neoadjuvant chemotherapy is safe and has few side effects. It can greatly reduce the level of tumor marker values in treating IIIA stage NSCLC patients after operation.